Next Article in Journal
Characterization of Hemagglutinin Antigens on Influenza Virus and within Vaccines Using Electron Microscopy
Next Article in Special Issue
Postgenomic Approaches and Bioinformatics Tools to Advance the Development of Vaccines against Bacteria of the Burkholderia cepacia Complex
Previous Article in Journal
Clinical Advances in Viral-Vectored Influenza Vaccines
Previous Article in Special Issue
Meningococcal Vaccines: Current Status and Emerging Strategies
Article Menu

Export Article

Open AccessArticle
Vaccines 2018, 6(2), 30;

Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment

Infectious Disease Research Institute, Seattle, WA 98102, USA
Department of Global Health, University of Washington, Seattle, WA 98195, USA
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA
PAI Life Sciences Inc., Seattle, WA 98102, USA
Author to whom correspondence should be addressed.
Received: 30 April 2018 / Revised: 18 May 2018 / Accepted: 22 May 2018 / Published: 24 May 2018
(This article belongs to the Collection Vaccines Against Chronic and Persistent Bacterial Infections)
Full-Text   |   PDF [2784 KB, uploaded 24 May 2018]   |  


It is estimated that one third of the world’s population is infected with Mycobacterium tuberculosis (Mtb). This astounding statistic, in combination with costly and lengthy treatment regimens make the development of therapeutic vaccines paramount for controlling the global burden of tuberculosis. Unlike prophylactic vaccination, therapeutic immunization relies on the natural pulmonary infection with Mtb as the mucosal prime that directs boost responses back to the lung. The purpose of this work was to determine the protection and safety profile over time following therapeutic administration of our lead Mtb vaccine candidate, ID93 with a synthetic TLR4 agonist (glucopyranosyl lipid adjuvant in a stable emulsion (GLA-SE)), in combination with rifampicin, isoniazid, and pyrazinamide (RHZ) drug treatment. We assessed the host inflammatory immune responses and lung pathology 7–22 weeks post infection, and determined the therapeutic efficacy of combined treatment by enumeration of the bacterial load and survival in the SWR/J mouse model. We show that drug treatment alone, or with immunotherapy, tempered the inflammatory responses measured in brochoalveolar lavage fluid and plasma compared to untreated cohorts. RHZ combined with therapeutic immunizations significantly enhanced TH1-type cytokine responses in the lung over time, corresponding to decreased pulmonary pathology evidenced by a significant decrease in the percentage of lung lesions and destructive lung inflammation. These data suggest that bacterial burden assessment alone may miss important correlates of lung architecture that directly contribute to therapeutic vaccine efficacy in the preclinical mouse model. We also confirmed our previous finding that in combination with antibiotics therapeutic immunizations provide an additive survival advantage. Moreover, therapeutic immunizations with ID93/GLA-SE induced differential T cell immune responses over the course of infection that correlated with periods of enhanced bacterial control over that of drug treatment alone. Here we advance the immunotherapy model and investigate reliable correlates of protection and Mtb control. View Full-Text
Keywords: therapeutic vaccine; Mycobacterium tuberculosis; tuberculosis; immunotherapy; adjuvant; GLA-SE; ID93 therapeutic vaccine; Mycobacterium tuberculosis; tuberculosis; immunotherapy; adjuvant; GLA-SE; ID93

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Larsen, S.E.; Baldwin, S.L.; Orr, M.T.; Reese, V.A.; Pecor, T.; Granger, B.; Dubois Cauwelaert, N.; Podell, B.K.; Coler, R.N. Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment. Vaccines 2018, 6, 30.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top